Patrik Pöschke1, Julius Emons1, Felix Heindl2, Rüdiger Schulz-Wendtland3, Sebastian Jud1,4, Ramona Erber5, Carolin C Hack1, Caroline Preuss1, Annika Behrens1. 1. Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. 2. Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany; felix.heindl@uk-erlangen.de. 3. Institute of Diagnostic Radiology, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. 4. Department of Gynecology and Obstetrics, Klinikum Mutterhaus der Borromaeerinnen, Trier, Germany. 5. Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract
BACKGROUND/AIM: Smaller, earlier-stage breast tumors are being found in breast cancer screening, and neoadjuvant chemotherapy is the gold standard when chemotherapy is indicated. Precise marking and localization of the tumor are thus becoming increasingly important. Wire-free localization techniques are under investigation in order to reduce presurgical radiography, pain, the risk of wire dislocation, and allow scheduling flexibility for patients and surgery departments. PATIENTS AND METHODS: This single-center observational study from June 2020 to October 2021 included 15 patients with mammographically or sonographically detected nonpalpable breast lesions. Radiofrequency identification (RFID) tags were placed preoperatively under ultrasound or radiologic guidance to localize lesions for planned surgery. All patients underwent breast conservation surgery, including one bilateral and one targeted axillary dissection. RESULTS: Histology identified two benign and 13 malignant lesions, including three ductal carcinomas in situ and 11 invasive breast cancers. Placement, control radiography, and handling of the RFID tag were feasible in everyday routine for different radiologists and surgeons and managed cost-effectively. All of the RFID tags were found in the specimen radiographs. CONCLUSION: The feasibility and cost-effectiveness of this non-wire localization method were demonstrated in this rather small cohort of patients. Further studies including larger numbers of patients are needed to confirm the method's accuracy.
BACKGROUND/AIM: Smaller, earlier-stage breast tumors are being found in breast cancer screening, and neoadjuvant chemotherapy is the gold standard when chemotherapy is indicated. Precise marking and localization of the tumor are thus becoming increasingly important. Wire-free localization techniques are under investigation in order to reduce presurgical radiography, pain, the risk of wire dislocation, and allow scheduling flexibility for patients and surgery departments. PATIENTS AND METHODS: This single-center observational study from June 2020 to October 2021 included 15 patients with mammographically or sonographically detected nonpalpable breast lesions. Radiofrequency identification (RFID) tags were placed preoperatively under ultrasound or radiologic guidance to localize lesions for planned surgery. All patients underwent breast conservation surgery, including one bilateral and one targeted axillary dissection. RESULTS: Histology identified two benign and 13 malignant lesions, including three ductal carcinomas in situ and 11 invasive breast cancers. Placement, control radiography, and handling of the RFID tag were feasible in everyday routine for different radiologists and surgeons and managed cost-effectively. All of the RFID tags were found in the specimen radiographs. CONCLUSION: The feasibility and cost-effectiveness of this non-wire localization method were demonstrated in this rather small cohort of patients. Further studies including larger numbers of patients are needed to confirm the method's accuracy.
Authors: R Schulz-Wendtland; P Dankerl; G Dilbat; M Bani; P A Fasching; K Heusinger; M P Lux; C R Loehberg; S M Jud; C Rauh; C M Bayer; M W Beckmann; D L Wachter; M Uder; M Meier-Meitinger; B Brehm Journal: Geburtshilfe Frauenheilkd Date: 2015-01 Impact factor: 2.915
Authors: Maggie L DiNome; Amy M Kusske; Deanna J Attai; Cheryce P Fischer; Anne C Hoyt Journal: Breast Cancer Res Treat Date: 2019-01-28 Impact factor: 4.872
Authors: Benjamin K Y Chan; Jill A Wiseberg-Firtell; Ramesh H S Jois; Katrin Jensen; Riccardo A Audisio Journal: Cochrane Database Syst Rev Date: 2015-12-31
Authors: Christoph Thomssen; Tanja N Fehm; Elmar Stickeler; Peter A Fasching; Wolfgang Janni; Cornelia Kolberg-Liedtke; Hans-Christian Kolberg; Diana Lüftner; Volkmar Müller; Florian Schütz; Erik Belleville; Simon Bader; Michael Untch; Manfred Welslau; Marc Thill; Andreas D Hartkopf; Hans Tesch; Nina Ditsch; Michael P Lux; Achim Wöckel; Bahriye Aktas; Andreas Schneeweiss; Rachel Würstlein Journal: Geburtshilfe Frauenheilkd Date: 2022-02-11 Impact factor: 2.915